公开(公告)号：US20250019374A1

公开(公告)日：2025-01-16

申请号：US18709214

申请日：2022-11-10

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Andrew Bogdan ,  Elliot P. Farney ,  Jennifer M. Frost ,  Philip R. Kym ,  Zhaoming Xiong ,  Naomi Anne Barton ,  Claire Anne Marie Cariou-Mumford ,  Christopher Patrick McMahon ,  Giuseppe Nano

IPC: C07D417/04 ,  A61K31/433 ,  A61K31/454 ,  C07D417/14

Abstract: The present invention provides for compounds of Formula (I) (I); wherein R2, X, and Z have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.

公开(公告)号：US20200299246A1

公开(公告)日：2020-09-24

申请号：US16892786

申请日：2020-06-04

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Geoff T. Halvorsen ,  Jennifer M. Frost ,  Philip R. Kym

IPC: C07D285/10

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

公开(公告)号：US20250042894A1

公开(公告)日：2025-02-06

申请号：US18709204

申请日：2022-11-10

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Andrew Bogdan ,  Christos Economou ,  Jennifer M. Frost ,  Philip R. Kym ,  Spencer O. Scholz ,  Zhaoming Xiong

IPC: C07D417/14 ,  A61K31/433 ,  C07D417/04

Abstract: The present invention provides for compounds of Formula (I) wherein R1, has any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.

公开(公告)号：US10954202B2

公开(公告)日：2021-03-23

申请号：US17025644

申请日：2020-09-18

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Zhaoming Xiong ,  Jennifer M. Frost ,  Philip R. Kym ,  Xueqing Wang ,  Shuang Chen ,  Dennie Welch

IPC: C07D285/10

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

公开(公告)号：US20210009542A1

公开(公告)日：2021-01-14

申请号：US17025644

申请日：2020-09-18

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Zhaoming Xiong ,  Jennifer M. Frost ,  Philip R. Kym ,  Xueqing Wang ,  Shuang Chen ,  Dennie Welch

IPC: C07D285/10

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

公开(公告)号：US20230019236A1

公开(公告)日：2023-01-19

申请号：US17807292

申请日：2022-06-16

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Elliot P. Farney ,  Reza Shiroodi ,  Zhaoming Xiong ,  Qingwei Zhang ,  Matthew J. O'Connor ,  Geoff T. Halvorsen ,  Hongyu Zhao ,  Christina Baumgartner ,  Jennifer M. Frost ,  Philip R. Kym ,  Jason R. Abbott ,  Andrew Bogdan ,  Christos Economou ,  Xueqing Wang

IPC: A61K31/433 ,  A61K39/395 ,  A61P35/00 ,  C07D417/10 ,  A61K31/5377 ,  C07D285/06

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

公开(公告)号：US10851073B2

公开(公告)日：2020-12-01

申请号：US16892786

申请日：2020-06-04

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Geoff T. Halvorsen ,  Jennifer M. Frost ,  Philip R. Kym

IPC: C07D285/10

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

公开(公告)号：US20240024338A1

公开(公告)日：2024-01-25

申请号：US18334738

申请日：2023-06-14

Applicant: AbbVie Inc.

Inventor： Benoit Cardinal-David ,  Vincent S. Chan ,  Kassibla E. Dempah ,  Brian P. Enright ,  Rodger F. Henry ,  Raimundo Ho ,  Ye Huang ,  Alexander D. Huters ,  Russell C. Klix ,  Scott W. Krabbe ,  Philip R. Kym ,  Yanbin Lao. ,  Xiaochun Lou ,  Sean Mackey ,  Mark A. Matulenko ,  Peter T. Mayer ,  Christopher P. Miller ,  James Stambuli ,  Valentino J. Stella ,  Eric A. Voight ,  Zhi Wang ,  Geoff G. Zhang

IPC: A61K31/661 ,  A61K9/00 ,  A61K9/14 ,  A61K45/06 ,  A61K9/08 ,  C07F9/12

CPC classification number: A61K31/661 ,  A61K9/0019 ,  A61K9/14 ,  A61K45/06 ,  A61K9/08 ,  C07F9/12

Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

公开(公告)号：US20130345255A1

公开(公告)日：2013-12-26

申请号：US13922442

申请日：2013-06-20

Applicant: AbbVie Inc.

Inventor： Arthur Gomtsyan ,  Jerome Daanen ,  Michael E. Kort ,  Philip R. Kym ,  Eric A. Voight ,  Kevin R. Woller

IPC: C07C317/28 ,  A61K31/192 ,  A61K31/353 ,  A61K31/436 ,  A61K31/352 ,  C07D311/96 ,  C07D491/052 ,  A61K31/18 ,  C07D311/68

CPC classification number: C07C317/28 ,  A61K31/18 ,  A61K31/192 ,  A61K31/352 ,  A61K31/353 ,  A61K31/436 ,  C07C311/08 ,  C07C2602/08 ,  C07D263/48 ,  C07D311/68 ,  C07D311/96 ,  C07D401/04 ,  C07D417/12 ,  C07D491/052

Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，前药或其组合，其中X1，L，Rx，Ry，Rz，R1，R2，A，m，n，p，q和r定义在 规格。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：US20220153765A1

公开(公告)日：2022-05-19

申请号：US17378321

申请日：2021-07-16

Applicant: AbbVie Inc.

Inventor： Benoit Cardinal-David ,  Vincent S. Chan ,  Kassibla Dempah ,  Brian P. Enright ,  Rodger F. Henry ,  Raimundo Ho ,  Ye Huang ,  Alexander D. Huters ,  Russell C. Klix ,  Scott W. Krabbe ,  Philip R. Kym ,  Yanbin Lao ,  Xiaochun Lou ,  Sean E. Mackey ,  Mark A. Matulenko ,  Peter T. Mayer ,  Christopher P. Miller ,  James Stambuli ,  Valentino J. Stella ,  Eric A. Voight ,  Zhi Wang ,  Geoff G. Zhang

IPC: C07F9/09 ,  A61K31/661 ,  C07F9/06 ,  C07C281/02 ,  C07C309/24 ,  C07C47/277 ,  A61K31/6615 ,  A61K45/06

Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.